Natural killer cells in carcinomatous pleural effusions

Uchida, Atsushi; Micksche, M.

doi:10.1007/bf00199264

Cited by 24 publications

(26 citation statements)

References 23 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The response was expressed both as the aggregation angle alpha and as the maximal amplitude. N K cell activity was studied as previously described in detail [34] using the patients' isolated mononuclear bone marrow and peripheral blood cells as effector cell populations, with 51Cr-labeled K562 cells as targets. Briefly, 100 ~tl 51Cr-labeled target cells and 100 lxl effector cells were placed into round-bottomed wells of microtiter plates (Nunc, Rokskilde, Denmark) at effector/target ratios of 40: 1, 20: 1, and 10: 1.…”

Section: Methodsmentioning

confidence: 99%

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

Ludwig

Linkesch

Gisslinger

et al. 1987

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

During previous therapeutic trials with interferon, decreased levels of peripheral platelet counts have been observed. Taking advantage of this effect, we investigated the efficacy of recombinant interferon (rec-IFN) in the treatment of thrombocytosis in myeloproliferative diseases. A total of 15 patients with polycythemia vera, essential thrombocytosis, or chronic myeloid leukemia received rec-IFN-alfa at initial doses of 25-70 x 10(6) units/week; maintenance therapy following week 8 of treatment consisted of 20-35 x 10(6) units/week rec-IFN. Observation periods ranged from 24 to 48 weeks. Significant reductions in the number of platelets were noted in all cases; 12/15 patients achieved platelet counts below 440 x 10(9)/l and maintained those normal values for at least 4 weeks. The number of bone marrow megakaryocytes, which had been increased prior to treatment, diminished during rec-IFN therapy, while the previously shortened platelet half-life further decreased with rec-IFN treatment. During rec-IFN-induced remission, the plasma levels of platelet factors, the activity of natural killer cells, and platelet aggregation showed changes between slight improvement and normal values. Severe side effects were only observed with the highest rec-IFN doses; dosage adjustments were effective in improving or eliminating all treatment-related symptoms. Rec-IFN may prove to be a valuable therapeutic alternative to cytostatic treatment of thrombocytosis in myeloproliferative disorders.

show abstract

Section: Methodsmentioning

confidence: 99%

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

Ludwig

Linkesch

Gisslinger

et al. 1987

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cytotoxicity of malignant pleural effusion lymphocytes (MPEL) against autologous tumor cells was compared with that of peripheral blood lymphocytes (PBL). The cytotoxicity of MPEL was found to be lower than that of PBL [23][24][25]. An evaluation of lymphocytes in nonsmall-cell lung cancer shows a decrease in the percentage of NK cells which has been reduced in TILs as compared to PBLs.…”

Section: Discussionmentioning

confidence: 99%

Correlation between DNA Content, Expression of Ki-67 Antigen of Tumor Cells and Immunophenotype of Lymphocytes from Malignant Pleural Effusions

Sikora¹,

Dworacki²,

Trybus³

et al. 1998

Tumor Biol

View full text Add to dashboard Cite

Malignant cells isolated from 26 malignant pleural effusions, collected from patients bearing metastatic carcinoma, were examined using flow cytometry. Expression of Ki-67 antigen, DNA ploidy, S phase fraction, DNA index of tumor cells and the percentage of aneuploid cell populations were determined. Lymphoid cells from the same malignant effusions and from 10 nonmalignant ones were examined using a panel of monoclonal antibodies (mAb) versus several CD antigens. While the percentages of T cells (CD3+, CD4+, CD8+) and B cells (CD19+) did not differ significantly in malignant versus nonmalignant effusions, those of CD56+ lymphocytes were found to be significantly depressed in malignant diploid and malignant aneuploid effusions as compared to benign ones. Expression of IL-2 receptors on lymphocytes, demonstrated by anti-CD25 mAb, was significantly higher in malignant diploid and malignant aneuploid effusions as compared with nonmalignant ones. An increase in the percentage of Ki-67-positive malignant cells was significantly correlated with the decrease of NK cells. S phase fraction, DNA index and the percentage of aneuploid populations did not correlate with the picture of lymphoid cells from pleural effusion. On the other hand, the percentage of Ki-67-positive tumor cells in pleural effusions was inversely proportional to the patients’ survival time, although it was not statistically significant. Our data suggest that the poor prognosis of cancer characterized by the presence of an aneuploid cell population of malignant cells and the high percentage of proliferating cells in pleural effusions can be linked to the depression of NK cells.

show abstract

“…The mechanism of action is, however, a matter of controversy. It has been suggested that induction of IFN is not involved in augmentation of NK activity by this agent (Uchida & Micksche, 1982 Although suppressor mechanisms can be demonstrated in the ascites of some ovarian cancer patients (Allavena et al, 1981;Introna et al, 1982) evidence has suggested that defective NK activity of TAL was mainly related to a low frequency of LGL (Introna et al, 1983;Introna & Mantovani, 1983) unlike pleural effusions where high numbers of LGL were reported (Uchida & Micksche, 1981a). Hence it appears unlikely that interference with suppressor mechanisms plays a major role in boosting of NK activity of TAL from ascites ovarian tumours.…”

Section: Discussionmentioning

confidence: 99%

Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells

Colotta¹,

Colombo²,

Tabacchi³

et al. 1983

Br J Cancer

View full text Add to dashboard Cite

Summary The streptococcal preparation OK432 was studied for its effects on natural killer (NK) activity of peripheral blood lymphocytes (PBL) from normal donors and from ovarian cancer patients, and of tumourassociated lymphocytes (TAL) from peritoneal effusions. OK432 augmented NK activity against the susceptible K562 line and induced killing of the relatively resistant Raji line. Freshly isolated ovarian carcinoma cells were relatively resistant to killing by unstimulated PBL and TAL. OK432 induced significant, though low, levels of cytotoxicity against 5'Cr-labelled ovarian carcinoma cells. Augmentation of killing of fresh tumour cells by OK432 was best observed in a 20h assay and both autologous and allogeneic targets were lysed. PBL were separated on discontinuous Percoll gradients. Unstimulated and OK432-boosted activity were enriched in the lower density fractions where large granular lymphocytes (LGL) and activity against K562 were found. Thus, OK432 augments NK activity of PBL and TAL in human ovarian carcinomas and induces low, but significant, levels of killing of fresh tumour cells. Effector cells involved in killing of fresh ovarian tumours copurify with LGL on discontinuous gradients of Percoll.

show abstract

Natural killer cells in carcinomatous pleural effusions

Abstract: Summary. Effector cells in carcinomatous pleural

Cited by 24 publications

References 23 publications

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders

Correlation between DNA Content, Expression of Ki-67 Antigen of Tumor Cells and Immunophenotype of Lymphocytes from Malignant Pleural Effusions

Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells

Contact Info

Product

Resources

About